uÀЉîAƒXƒ^ƒbƒtЉîAŒ¤‹†A‹ÆÑ“™A‡“V“°‘åŠw‘åŠw‰@ ŽY•wl‰ÈŠw‚ÉŠÖ‚·‚é—lX‚Èî•ñ‚ð‚²ˆÄ“à‚µ‚Ü‚·B

‡“V“°‘åŠw‘åŠw‰@@ŠeŒ¤‹†•ª–ìЉî@l‘̶̂–½‹@”\

‹ÆÑ

¡‹ÆÑ

¡‹ÆÑi˜_•¶j2015”N
Œ¤‹†”ï | ‰p•¶Œ´’˜ | ‰p•¶‘à | ˜a•¶Œ´’˜ | ‰p•¶•ñ | ˜a•¶•ñ | ˜a•¶‘à | ˜a•¶’˜‘ |
µ‘Òu‰‰i‘Ûj | µ‘Òu‰‰i‘“àj‚»‚Ì‘¼iL•ñŠˆ“®‚ðŠÜ‚Þj |
Œ¤‹†”ï
  1. Œ¤‹†‘ã•\ŽÒF‰¡ŽR ˜amAŒ¤‹†•ª’SŽÒF’|“c@ÈA´…@r–¾Aç—t@•SŽqAƒ‚[ƒZƒ“@ƒ”ƒB[ƒWƒFA¼‰ª@ÎŽqA–k‘º@•¶•FA×ì@‚Ü‚äŽqA¼ì@ŠxD•½¬27”N“x(2015”N“x) Šî”ÕŒ¤‹†i‚ajiŠCŠOŠwp’²¸jŒ¤‹†Œv‰æ’²‘@ŠJ”­“rã‘‚É‚¨‚¯‚éŠÂ‹«‰˜õ‚Ì¬Ž™Œ’N‰e‹¿‚ÉŠÖ‚·‚é‘Û‹¤“¯Œ¤‹†
  2. ’|“c@ÈA–q–ì^‘¾˜YD•½¬2‚V”N“x“ú•ꂨ‚¬‚á[Œ£‹àŠî‹à100–œ‰~@V¶Ž™’áŽ_‘f«‹•ŒŒ«”]ǂɂ¨‚¯‚écaspase-6‚ÌV‚½‚È–ðŠ„‚É‚Â‚¢‚Ä
  3. ¼‘º@—DŽqAŒ¤‹†•ª’SŽÒFÜ–Î@²AŽ›”ö@‘׋vA”ó–ì@‹»•vD•½¬27”N“x@Šw’·“Á•Ê‹¤“¯ƒvƒƒWƒFƒNƒgŒ¤‹†@Šà“àüˆÛ‰è×–E‚É‚æ‚é“ûŠà“]ˆÚ‘£i‹@\‚É‚¨‚¯‚éˆâ“`Žqƒlƒbƒgƒ[ƒN‚̉𖾌¤‹†‘ã•\ŽÒ
  4. ’|“c@ƒ@Œ¤‹†•ª’SŽÒ:‚…@—•Ar–ØŒc•FA”‘q“Ö•vA’|“c@ÈD•½¬27”N“x@Šw’·“Á•Ê‹¤“¯ƒvƒƒWƒFƒNƒgŒ¤‹†@ƒqƒg––½ŒŒ”’ŒŒ‹…‚̳ŠúŽYE‘ŽY‚É‚¨‚¯‚镪•ØŠJŽn‚ɑ΂·‚é–ðŠ„‚É‚Â‚¢‚Ä
  5. Œ¤‹†‘ã•\ŽÒ:¬Š}Œ´@‰xŽq (—«ƒXƒ|[ƒcŒ¤‹†ƒZƒ“ƒ^[‘åŠw‰@ƒXƒ|[ƒcŒ’N‰ÈŠwŒ¤‹†‰È‹³Žö)D•½¬27 ”N“x@•¶•”‰ÈŠwÈ@Ž„—§‘åŠwí—ª“IŒ¤‹†Šî”ÕŒ`¬Žx‰‡Ž–‹Æ —«ƒXƒ|[ƒcŒ¤‹†ƒZƒ“ƒ^[‚É‚¨‚¯‚é—«ƒAƒXƒŠ[ƒgƒRƒ“ƒfƒBƒVƒ‡ƒ“ŠÇ—‚ÉŠÖ‚·‚錤‹†Šî”Õ\’z
  6. ˆäã‘(é‹Êˆã‘åƒQƒmƒ€ˆãŠwŒ¤‹†ƒZƒ“ƒ^[Eˆâ“`Žq§Œä•”–åE•”–å’·), •ª’SŒ¤‹†ŽÒF’|“c@ÈDŒŽŒo’²®‚ƃRƒ“ƒfƒBƒVƒ‡ƒ“ŠÇ—ƒvƒƒOƒ‰ƒ€ŠJ”­Œ¤‹†@ˆâ“`Žq‰ü•ÏŽÀŒ±“®•¨ƒ‚ƒfƒ‹‚ð—p‚¢‚½œE‹Ø“÷E‰^“®”\‚É‚¨‚¯‚éƒXƒeƒƒCƒhƒzƒ‹ƒ‚ƒ“‚Ì–ðŠ„@700–œ‰~D
  7. Œ¤‹†ŠJ”­‘ã•\ŽÒF‹gì—T”VA•ª’SŽÒF’|“c@ÈA‘¼D“ú–{ˆã—ÃŒ¤‹†ŠJ”­‹@\ˆÏ‘õŒ¤‹†@ã”ç«—‘‘ƒ‚ª‚ñ‚Ì”D›s«‰·‘¶Ž¡—Â̑ÎÛŠg‘å‚Ì‚½‚߂̔ñƒ‰ƒ“ƒ_ƒ€‰»ŒŸØ“IŽŽŒ±
‰p•¶Œ´’˜
  1. Ujihira T, Ikeda K, Suzuki T, Yamaga R, Sato W, Horie-Inoue K, Shigekawa T, Osaki A, Saeki T, Okamoto K, Takeda S, Inoue S.
    MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer.
    Sci Rep. 2015 Jan 6;5:7641. doi: 10.1038/srep07641.
  2. Verstraeten BSE, Mijovic-Kondejewski J, Takeda J, Tanaka S, Olson DM.
    Canadafs pregnancy-related mortality rates: doing well but room for improvement.
    Clin Invest Med 2015;38:
  3. Makino S, Takeda J, Hirai C, Itakura A, Takeda S.
    Uterine balloon tamponade as a test to assess the further treatment.
    Acta Obstet Gynecol Scand. 2015 Feb 2. doi: 10.1111/aogs.12599.
  4. Kato T, Takashima A, Kasamatsu T, Nakamura K, Mizusawa J, Nakanishi T, Takeshima N, Kamiura S, Onda T, Sumi T, Takano M, Nakai H, Saito T, Fujiwara K, Yokoyama M, Itamochi H, Takehara K, Yokota H, Mizunoe T, Takeda S, Sonoda K, Shiozawa T, Kawabata T, Honma S, Fukuda H, Yaegashi N, Yoshikawa H, Konishi I, Kamura T; on behalf of Gynecologic Oncology Study Group of the Japan Clinical Oncology Group. FClinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A).@Gynecol Oncol. 2015 Feb 7. pii: S0090-8258(15)00591-0. doi:10.1016/j.ygyno.2015.01.548.
  5. Nishioka E, Hirayama S, Ueno T, Matsukawa T, Vigeh M, Yokoyama K, Makino S, Takeda S, Miida T.
    Relationship between maternal thyroid-stimulating hormone (TSH) elevation during pregnancy and low birth weight: A longitudinal study of apparently healthy urban Japanese women at very low risk.
    Early Hum Dev. 2015 Feb 9;91(3):181-185. doi: 10.1016/j
  6. Sone M, Nakajima Y, Woodhams R, Shioyama Y, Tsurusaki M, Hiraki T, Yoshimatsu M, Hyodoh H, Kubo T, Takeda S, Minakami H.
    Interventional radiology for critical hemorrhage in obstetrics: Japanese Society of Interventional Radiology (JSIR) procedural guidelines.
    Jpn J Radiol. 2015 Apr;33(4):233-40. doi: 10.1007/s11604-015-0399-0.
  7. Baburamani AA, Miyakuni Y, Vontell R, Supramaniam VG, Svedin P, Rutherford M, Gressens P, Mallard C, Takeda S, Thornton C, Hagberg H.
    Does Caspase-6 Have a Role in Perinatal Brain Injury?
    Dev Neurosci. 2015 Mar 24. [Epub ahead of print]
  8. Shimanuki Y, Mitomi H, Fukumura Y, Makino S, Itakura A, Yao T, Takeda S.
    Alteration of Delta-like ligand 1 and Notch 1 receptor in various placental disorders with special reference to early onset preeclampsia.
    Hum Pathol. 2015 Apr 16. pii: S0046-8177(15)00116-1. doi:
  9. Murakami M, Kobayashi T, Kubo T, Hata T, Takeda S, Masuzaki H.
    Experience with recombinant activated factor VII for severe post-partum hemorrhage in Japan, investigated by Perinatology Committee, Japan Society of Obstetrics and Gynecology.
    J Obstet Gynaecol Res. 2015 May 25. doi: 10.1111/jog.12712.
  10. Makino S, Takeda S, Kobayashi T, Murakami M, Kubo T, Hata T, Masuzaki H.
    National survey of fibrinogen concentrate usage for post-partum hemorrhage in Japan: Investigated by the Perinatology Committee, Japan Society of Obstetrics and Gynecology.
    J Obstet Gynaecol Res. 2015 May 27. doi: 10.1111/jog.12708.
  11. Ueki N, Takeda S, Koya D, Kanasaki K.
    The relevance of the Renin-Angiotensin system in the development of drugs to combat preeclampsia.
    Int J Endocrinol. 2015;2015:572713. doi: 10.1155/2015/572713. Epub 2015 Apr 27. Review.
  12. Hamamura K, Nonaka D, Ishikawa H, Banzai M, Yanagida M, Nojima M, Yoshida K, Lee LJ, Tanaka K, Takamori K, Takeda S, Araki Y.
    Simple quantitation for potential serum disease biomarker peptides, primarily identified by a peptidomics approach in the serum with hypertensive disorders of pregnancy.
    Ann Clin Biochem. 2015 Apr 2. pii: 0004563215583697.
  13. Ikuma S, Sato T, Sugiura-Ogasawara M, Nagayoshi M, Tanaka A, Takeda S.
    Preimplantation Genetic Diagnosis and Natural Conception: A Comparison of Live Birth Rates in Patients with Recurrent Pregnancy Loss Associated with Translocation.
    PLoS One. 2015 Jun 17;10(6):e0129958. doi: 10.1371/journal.pone.0129958.
  14. Makino S, Hirai C, Itakura A, Takeda S, Yoshikawa H, Li Z, Kawabata KI, Tanaka H.
    Evaluation of uterine blood flow: a new method using contrast-enhanced ultrasound.
    Eur J Obstet Gynecol Reprod Biol. 2015 Jun 4. pii: S0301-2115(15)00137-2. doi:
    10.1016/j.ejogrb.2015.04.009.
  15. Takeda, J, Kikuchi, I, Kono, A, Ozaki, R, Kumakiri, J, Takeda, SD
    Efficacy of short-term training for acquisition of basic laparoscopic skillsD
    Gynecology and Minimally Invasive Therapy@@Available online 26 June 2015
  16. Hiromi Yamada, Yoko Tabe, Kiyoshi Ishii, Yasuhisa Terao, Yohei Yamashita, Takashi Horii, Satoru Takeda, Akimichi Ohsaka
    Clinical Performance Evaluation of a High-Risk Human@Papillomavirus Genotyping Test gClinichip HPVh@Using Cervical Scrape Specimens.
    Clin. Lab. 2015;61:851-855
  17. Inagaki T, Kusunoki S, Tabu K, Okabe H, Yamada I, Taga T, Matsumoto A, Makino S, Takeda S, Kato K.
    Up-regulation of lymphocyte antigen 6 complex expression in side-population cells derived from a human trophoblast cell line HTR-8/SVneo.
    Hum Cell. 2015 Jul 30. [Epub ahead of print]
  18. Hara K, Fukumura Y, Saito T, Arakawa A, Okabe H, Takeda S, Yao T.
    A giant cord hemangioma with extramedullary hematopoiesis and elevated maternal serum human chorionic gonadotropin: a case report and review of the literature.
    Diagn Pathol. 2015 Sep 4;10(1):154. doi: 10.1186/s13000-015-0385-y.
  19. Lucas ES, Dyer NP, Murakami K, Lee YH, Chan YW, Grimaldi G, Muter J, Brighton PJ, Moore JD, Patel G, Chan JK, Takeda S, Lam EW, Quenby S, Ott S, Brosens JJ.
    Loss of Endometrial Plasticity in Recurrent Pregnancy Loss.
    Stem Cells. 2015 Sep 29. doi: 10.1002/stem.2222. [Epub ahead of print]
  20. Tanaka, A, Nagayoshi, M, Takemoto, Y, Tanaka, I, Kusunoki, H, Watanabe, S , Kuroda,K, Takeda, S, Ito, M, Yanagimachi, R
    Fourteen babies born after round spermatid injection into human oocytes
    PNAS 2015 ; published ahead of print November 2, 2015, doi:10.1073/pnas.1517466112
  21. Chigusa Y, Kawasaki K, Kondoh E, Mogami H, Ujita M, Fujita K, Tatsumi K, Takeda S, Konishi I.FSimvastatin inhibits oxidative stress via the activation of nuclear factor erythroid 2-related factor 2 signaling in trophoblast cells.
    J Obstet Gynaecol Res. 2015 Nov 10. doi: 10.1111/jog.12876.
  22. Kuroda K, Kitade M, Kumakiri J, Jinushi M, Shinjo A, Ozaki R, Ikemoto Y, Katoh N, Takeda S.FMinimum ovarian stimulation involving combined clomiphene citrate and estradiol treatment for in vitro fertilization of Bologna-criteria poor ovarian responders.
    J Obstet Gynaecol Res. 2015 Nov 10. doi: 10.1111/jog.12862.
  23. Suzuki S, Takeuchi T, Okano T, Kamiya N, Sugiyama T, Ebine M, Matsuda H, Suzuki T, Okai T, Takeda S, Ochiai K, Kinoshita K.
    Problems of Perinatal Mental Health Care in Tokyo, Japan.
    J Clin Med Res. 2015 Dec;7(12):1013. doi: 10.14740/jocmr2371w. Epub 2015 Oct 23.
  24. Takagi K, Yamasaki M, Nakamoto O, Saito S, Suzuki H, Seki H, Takeda S, Ohno Y, Sugimura M, Suzuki Y, Watanabe K, Matsubara K, Makino S, Metoki H, Yamamoto T
    A Review of Best practice guide 2015 for care and treatment of hypertension in pregnancy. Hypertens Res Pregnancy 2015;3:65-103
‰p•¶‘à
  1. Takagi K, Yamasaki M, Nakamoto O, Saito S, Suzuki H, Seki H, Takeda S, Ohno Y, Sugimura M, Suzuki Y, Watanabe K, Matsubara K, Makino S, Metoki H, Yamamoto TDA Review of Best practice guide 2015 for care and treatment of hypertension in pregnancyDHypertens Res Pregnancy 2015;3:65-103
  2. Baburamani AA, Miyakuni Y, Vontell R, Supramaniam VG, Svedin P, Rutherford M, Gressens P, Mallard C, Takeda S, Thornton C, Hagberg HDDoes Caspase-6 Have a Role in Perinatal Brain Injury?DDev Neurosci. 2015;37:321-37
  3. Ueki N, Takeda S, Koya D, Kanasaki KDThe relevance of the Renin-Angiotensin system in the development of drugs to combat preeclampsiaDInt J Endocrinol. 2015;2015:572713. doi: 10.1155/2015/572713.
  4. Verstraeten BSE, Mijovic-Kondejewski J, Takeda J, Tanaka S, Olson DMDCanada's pregnancy-related mortality rates: doing well but room for improvementDClin Invest Med. 2015 6;38:E15-22
˜a•¶Œ´’˜
  1. “c‘ã —Ç•F @‘œ T–ç, ™–{ ‹Nˆê, –öÀ sG, ¬“‡ –L, ŒÜ“¡ —Ï•q, ¡¼ r‰î, –ko ^—, ”ª”ö —²Žj, â–{ ˆê”ŽD’°•ÂÇ‚ð”­Ç‚µ‚½‰ñ’°Žq‹{“à–ŒÇ‚Ì1—áD “ú–{ŠO‰ÈŒn˜A‡Šw‰ïŽ 40;122-127,2015
  2. ˆË“¡ ’Žu, –q–ì ^‘¾˜Y, •½ˆä ç—T, ŽR–{ —S‰Ø, ”‘q “Ö•v, ’|“c ÈD”DPE•ª•ØEŽYåñŠú‚ÌŒŒðÇðÇ—\–h–@‚̉ۑèD“ú–{ŽY•wl‰ÈEV¶Ž™ŒŒ‰tŠw‰ïŽ,@2015; 24 : 47-52
  3. “í–Ø ‘Ži, ‘¾“c „Žu, ‹à“c —eG, Ž›”ö ‘׋v, ’|“c ÈDŽq‹{“à–ŒÇ«”X–E‚ÌŒo‰ßŠÏŽ@’†‚Ɉ««‰»‚ð‚«‚½‚µ‚½Ç—á‚ÌŒŸ“¢D“ú–{•wl‰ÈŽîᇊw‰ïŽGŽ@2015;33:29-35
  4. ìú±—D@ŒF؇@–ko^—@•“cŒbŽi@’nŽå½@´…‘€@Ž•½—R‹I@’r–{—TŽq@”öè—Œb@‘ºãŒ\—S@“c“‡‹±Žq@’|“cÈD• o‹¾‰ºŽèp‚É‚¨‚¯‚é“d“®ƒ‚ƒ‹ƒZƒŒ[ƒ^[‚ÌŽg—p‚ÉŠÖ‚·‚銳ŽÒˆÓޝ’²¸D“Œ‹žŽY‰È•wl‰ÈŠw‰ï‰ïŽ@64: 557-564A2015
  5. ŽÂŒ´@ŽO’ÃŽqA–xàV@MA’nŽå@½A–ko@^—AŒFØ@‡A•“c@ŒbŽiA”öè@—ŒbAVé@ˆ²A’|“c@ÈDƒGƒ“ƒhƒJƒƒŒƒIƒ“®‚ð—p‚¢‚½• o‹¾‰º—‘‘ƒ”XŽî“Eop@8—á‚ÌŒŸ“¢D“Œ‹žŽY‰È•wl‰ÈŠw‰ï‰ïŽA64F16-19, 2015
‰p•¶•ñ
  1. Makino S, Hirai C, Itakura A, Takeda S, Yoshikawa H, Li Z, Kawabata K, Tanaka HDEvaluation of uterine blood flow: a new method using contrast-enhanced ultrasoundDEur J Obstet Gynecol Reprod Biol. 2015; 191:143-4.
  2. Makino S, Takeda J, Hirai C, Itakura A, Takeda SDUterine balloon tamponade as a test to assess further treatmentDActa Obstet Gynecol Scand. 2015; 94:556
˜a•¶•ñ
  1. ŒFØ@‡, ‹e’n ”Õ, ŒK’ß —Ç•½, ’|“c ÈD‘½”­«Žq‹{‹ØŽî‚¨‚æ‚ÑŽq‹{‘B‹ØÇ‚ð—L‚µ‚½Ç—á‚ɑ΂·‚éŽq‹{“®–¬ÇðpŒã‚É’vŽ€“I”xÇð‚ð”­Ç‚µ‚½1—áDŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ïŽ 521;45-50, 2015
  2. ‹à“c —eG, “¡–ì ˆê¬, Ž•½ ’•¶, “í–Ø ‘Ži, –Ø‘º ”üˆ¨, Ž›”ö ‘׋v, –ko ^—, ”‘q “Ö•v, ’|“c ÈD•ª—tóèòŠÇ‘B‰ßŒ`¬‚ɑ΂µ• o‹¾‰ºŽq‹{‘S“Eop‚ðs‚¢pŒãŬ•Θߌ^”S‰t«‘BŠà‚Æf’f‚µ‚½1—áD“Œ‹žŽY‰È•wl‰ÈŠw‰ï‰ïŽ 64:246-252, 2015
  3. ‚‹´@‰ë–ç, ¬–ì@‹`‹v, ‘匴@Œ’, ¼‰i@–΄, ’·ˆä@’q‘¥, ‘ºŽR@Œh•F, ‚ˆä@‘×, Ö“¡@³”Ž, ”nê@ˆêŒ›, ŠÖ@”Ž”VD•ê‘ÌŽ€–S‚ÉŽŠ‚Á‚½ŽüŽYŠúS‹ØÇ‚Ì1—áDé‹ÊŒ§ˆãŠw‰ïŽGŽ, 50: 278-283, 2015
  4. ‚‹´@‰ë–ç, ‹à“c@—eG, Γc@‚ä‚è, ŽO—Ö@ˆ»Žq, ’·ˆä@çŽ÷, “í–Ø@‘Ži, –Ø‘º@”üˆ¨, Ž›”ö@‘׋v, ”‘q@“Ö•v, ’|“c@ÈDˆ««•F•\”çŽî‚ðŒ_‹@‚Éf’f‚ÉŽŠ‚Á‚½• –ŒŠà‚̈ê—áDŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ïŽ, 52F719-726, 2015
  5. •ìKAŽR–{—S‰ØA‘ºãŒ\—SA´…‘€A–q–ì^‘¾˜YA”‘q“Ö•vA’|“cÈD‘Šú‚Ì‘OŠú”j…‚É‚æ‚é’·Šú—r…‰ß­‚ÉŠÖ‚í‚炸A—ÇD‚ÈV¶Ž™—\Œã‚ð’æ‚µ‚½ˆê—áD“Œ‹žŽY•wl‰ÈŠw‰ï‰ïŽ,64:437-441, 2015
  6. ŽÂŒ´ ŽO’ÃŽq, –xàV M, ’nŽå ½, –ko ^—, ŒFØ@‡, •“c ŒbŽi, ”öè —Œb, Vé ˆ², ’|“c ÈDƒGƒ“ƒhƒJƒƒŒƒIƒ“‚ð—p‚¢‚½• o‹¾‰º—‘‘ƒ”XŽî“Eop8—á‚ÌŒŸ“¢D“Œ‹žŽY‰È•wl‰ÈŠw‰ï‰ïŽ 64;16-19, 2015
˜a•¶‘à
  1. ’|“c@ÈDˆÙŠ«”DPD¡“ú‚ÌŽ¡—ÃŽwj2015 57: 1231 ˆãŠw‘‰@
  2. ’|“c@ÈD“àfŠŒ©‚ł̎™“ª‚Ì‚‚³‚Ì•\Œ»‚ÉŠÖ‚·‚é’ñŒ¾@\\ˆÀ‘S‚È‹}‘¬‹•Øp‚Ì‚½‚ß‚É\\D“ú–{ŽY‰È•wl‰ÈŠw‰ïŽ67F2052|55A2015
  3. ’|“c@ÈD”D•w‹~‹}‘Ήž‚ÌŽÀ‘H‚ƈã—ÃVƒXƒeƒ€\’z‚Ì‚½‚ß‚É@Šw‰ï‚ÌŽæ‚è‘g‚Ý@“ú–{ŽY‰È•wl‰ÈŠw‰ïŽüŽYŠúˆÏˆõ‰ïDŽY•w‚ÌŽÀÛ64F1177A2015
  4. ’|“c@ÈDŽèp‚ª‚¢‚ç‚È‚¢H!V‚µ‚¢äTƒ_ƒCƒŒ[ƒ^|‚ð—p‚¢‚½”ñŠÏŒŒ“I‘¢äTpD“ú–{ˆãŽ–V•ñ4778F48A2015
  5. ’|“c@ÈD“àfŠŒ©‚ł̎™“ª‚Ì‚‚³‚Ì•\Œ»‚ÉŠÖ‚·‚é’ñŒ¾\\ˆÀ‘S‚È‹}‘¬‹•Øp‚Ì‚½‚ß‚É\\D“ú–{ŽY‰È•wl‰ÈŠw‰ïŽ67F2052|55, 2015
  6. ’|“c@ÈD”D•w‹~‹}‘Ήž‚ÌŽÀ‘H‚ƈã—ÃVƒXƒeƒ€\’z‚Ì‚½‚ß‚É@Šw‰ï‚ÌŽæ‚è‘g‚Ý@“ú–{ŽY‰È•wl‰ÈŠw‰ïŽüŽYŠúˆÏˆõ‰ïDŽY•w‚ÌŽÀÛ64F1177, 2015
  7. ’|“c@ÈDŽèp‚ª‚¢‚ç‚È‚¢H!V‚µ‚¢äTƒ_ƒCƒŒ[ƒ^|‚ð—p‚¢‚½”ñŠÏŒŒ“I‘¢äTpD“ú–{ˆãŽ–V•ñ4778F48, 2015
  8. ”‘q“Ö•vDŽüŽYŠúf—Âׂ©‚炸W •s‹K‘¥R‘ÌŒŸ¸—z«‚ð‚݂̂ª‚·‚ׂ©‚炸DŽüŽYŠúˆãŠw@45‘Ч†F34-36, 2015
  9. –ko^—DŽq‹{‹ØŽî‚ɑ΂·‚é’áNPŽ¡—Ãy“ÁWz@• o‹¾‰ºŽq‹{‹ØŽîŠjop‚̃gƒsƒbƒNƒXD“ú–{ŽY‰È•wl‰ÈŠw‰ïŽGŽ 67:1411-1419, 2015,
  10. –ko^—AŒE^—R”üD—«ƒAƒXƒŠ[ƒg‚ւ̃Tƒ|[ƒg‚ðl‚¦‚é@ŠCŠO‚ÉŠw‚Ô‡A-ƒAƒƒŠƒJŽ‹Ž@ƒŠƒ|[ƒg-DCoaching clinic 5ŒŽ†F22-25, 2015
  11. –ko^—DŽq‹{“à–ŒÇ‚Ì–ò•¨—Ö@@2.Žá”N—«‚ÌŽq‹{“à–ŒÇ‚ÌŽ¡—ÃFŽèp—Ö@‚àŠÜ‚ß‚ÄDÅV—«ˆã—à 2: 66-73, 2015
  12. –ko^—D—«ƒAƒXƒŠ[ƒgŠO—ˆ‚ÌÝ—§‚ÆŒ»ó@\—«ƒAƒXƒŠ[ƒg‚Ì’·Šú“I‚È‹£‹Z—ÍŒüã‚ð–ÚŽw‚µ‚Ä\D‡“V“°‘åŠwŽY•wl‰È“¯‘‹‰ïŽ .23-24 2015
  13. Ž›”ö ‘׋v, –ko ^—, ’|“c ÈD•wl‰ÈŽèp‚ƌ㕠–Œ‰ð–U@• o‹¾‰ºŽèp‚É‚¨‚¯‚éˆÀ‘SŠmŽÀ‚ÈŽèp‚ðs‚¤‚½‚߂̜”Õ—Õ°‰ð–U‚Ì—‰ðDŽY•wl‰ÈŽèp 26;109-113, 2015
  14. –q–ì^‘¾˜YDy”D•w‹~‹}‘Ήž‚ÌŽÀ‘H‚ƈã—ÃVƒXƒeƒ€\’z‚Ì‚½‚ß‚Éz ŽY‰È‹~‹}‚Ì“ÁŽê«@ŠO‰Èˆ’uDŽY•wl‰È‚ÌŽÀÛ@64: 1141-1146, 2015
  15. –q–ì^‘¾˜Y@ˆîŠ_“OŒPD•ª•ØŒãŠë‹@“IoŒŒ‚É‚¨‚¢‚Ä‘‚߂̗AŒŒŽè”z‚ð‘Ó‚é‚ׂ©‚炸DŽüŽYŠúf—Âׂ©‚炸W@45; 362, 2015
  16. ŽR–{—S‰ØA”‘q“Ö•vA’|“c@ÈD”DP’†ŒãŠú@‘ÙŽ™Œ`‘ÔˆÙíƒXƒNƒŠ[ƒjƒ“ƒOD—Õ•wŽY 69:632-638, 2015
  17. ’nŽå@½DERAS -ŽY•wl‰È—̈æ‚É‚¨‚¯‚éERAS-D—Õ°ŽGŽŠO‰È 77;175-179, 2015
  18. –xàV@MAŒFØ@‡A’|“c@ÈD•wl‰È—̈æ‚É‚¨‚¯‚é• o‹¾‰ºŽèp‚ÌŽå‚ÈpŽ®DŽèpŠÅŒìƒGƒLƒXƒp[ƒg@8G54-9, 2015
  19. “¡–ìˆê¬A’|“c@ÈD‹}«• Ç ‚æ‚­‚í‚©‚錟¸‚Æf’fDŽY‚Æ•w 28 suppl.:420-423, 2015
  20. •½ˆäç—T@”‘q“Ö•vD•wl‰È‡•¹Ç‚ւ̑Ήž‚̃Rƒc‚Æ—Ž‚Æ‚µŒŠDŽüŽYŠúˆãŠw@45F756-758, 2015
  21. •½ˆäç—T@–q–ì^‘¾˜YDèòŠÇ”DP‚ÆCesarean Scar Pregnancy(CSP)‚ւ̑ΉžDŽüŽYŠúˆãŠw@45F1057-1060, 2015
  22. •½ˆäç—T@–q–ì^‘¾˜YDDVT”­Ç—\–h‚ð‚©‚Ë‚½’鉤؊JpŒãáu’ÉŠÇ—‚ÌH•vDŽüŽYŠúˆãŠw@45F1758-1760, 2015
  23. •½ˆäç—T@’|“cÈD4. t޾㇕¹”DP\B. ‡•¹Ç”DP‚ÌŠÇ—‚ÆŽ¡—ÃDŽY‰È•wl‰È޾гÅV‚ÌŽ¡—à 2016-2018F115
  24. —é–Ø•qŽjE’ßú±”ü“¿E¼–{’¼’Ê Dˆâ“`«Ž¾Š³‚ÌŒ´ˆö‹†–¾‚É‚¨‚¯‚鎟¢‘ãƒV[ƒNƒGƒ“ƒX‚Ì—L—p« Dˆâ“`ŽqˆãŠw 28;32-37, 2015
  25. —é–Ø•qŽjE¼–{’¼’Ê DWDR45•ψقª‚Ђ«‹N‚±‚·“S’¾’…«_Œo•Ï«Ž¾Š³SENDAD“à•ª”åE“œ”A•aE‘ãŽÓ“à‰È@40;465-469, 2015
  26. ˆîŠ_“OŒP –q–ì^‘¾˜YD—AŒŒ»Ü‚Ì‘I’è–@EƒNƒƒXƒ}ƒbƒ`–@E“Š—^Žž‚Ì’ˆÓ‚ð‚í‚·‚ê‚é‚ׂ©‚炸DŽüŽYŠúf—Âׂ©‚炸W 45:, 360-361, 2015
  27. ’|“c@ƒA’|“c@ÈD”DP‡•¹Ç@‚—î”DP‚Æ‘O’u‘Ù”ÕDŽY•w‚ÌŽÀÛ64:509-515A2015
  28. ’|“cƒA’|“cÈD‚—î”DP‚ð’m‚éDŽY•wl‰È‚ÌŽÀÛ 64, 2015
  29. ’|“cƒA’|“cÈDŽüŽYŠúf—Âׂ©‚炸W@‹zˆø•ª•Ø‚ð‚È‚ñ‚ƂȂ­Ž{s‚·‚é‚ׂ©‚炸DŽüŽYŠúˆãŠw@45‘Ч†:388-390, 2015
  30. ’|“cƒA’|“cÈDŽüŽYŠúf—Âׂ©‚炸W@“àfŠŒ©‚ª•s³Šm‚Ȃ܂܂ÅççŽq•ª•Ø‚ðs‚¤‚ׂ©‚炸DŽüŽYŠúˆãŠw@45‘Ч†: 391-392, 2015
  31. ’r–{@—TŽqA’|“c@ÈD• o‹¾‰ºŽq‹{‹ØŽîŠjop‚É‚¨‚¯‚鋨ŽîŠj‚̉ñŽû•û–@D“ú–{ˆãŽ–V•ñ,@4781F54A2015
  32. ‘ºã Œ\—S , ’|“c ÈDŒŒŠÇŒ‹ãF–@ : stepwise devascularization (“ÁW ŽY‰ÈŽèp ŽÀ’n—Õ°‚̃Rƒc) -- (ŽYåñŽžEŽYåñ‘åoŒŒ‚Ö‚Ì‘Îô)DŽüŽYŠúˆãŠw 45, 1123-1125, 2015
  33. ˆÉ“¡ , ¼‘º—DŽqCˆÉ“¡‹±•FCÜ–Î ²DŠà“àüˆÛ‰è×–E‚ÆŠàˆ««‰»wŒÄ‹zxDŒÄ‹zŒ¤‹† 34:758-766, 2015
  34. Ü–Î ², ¼‘º—DŽq, –{‘½ˆê‹M, Nadila WaliDŠà“àüˆÛ‰è×–E‚ÆŠàˆ««‰»@Šà‚Ì”÷¬ŠÂ‹«‚Æ•W“IŽ¡—ÃDwŽÀŒ±ˆãŠwx—r“yŽÐ 33: 73-80, 2015
  35. Ü–Î ²@¼‘º—DŽqCˆÉ“¡‹±•FC\‡WìDüˆÛ‰»•a‘Ô‚ÆŠàˆ««‰»DwŒÄ‹zŠí“à‰Èx27:142-148, 2015
˜a•¶’˜‘
  1. ’|“c@Èi•]‰¿ˆÏˆõj•ÒW@‹}«• Çf—ÃKƒCƒhƒ‰ƒCƒ“o”ňψõ‰ïD‹}«• Çf—ÃKƒCƒhƒ‰ƒCƒ“2015DˆãŠw‘‰@@2015”N3ŒŽ1“ú
  2. ’|“c@Èi•ª’Sj •ÒW@“ú–{”DP‚ŒŒˆ³Šw‰ïD”DP‚ŒŒˆ³ÇŒóŒQ‚Ìf—ÃŽwj2015DƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N4ŒŽ1“ú
  3. •½ˆäç—TA’|“c@Èi•ª’S)D”DPŒãŠúAŽö“ûŠú ‰ž—p‰h—{Šw@‘æ10”Å@ƒ‰ƒCƒtƒXƒe[ƒW‚©‚ç‚Ý‚½lŠÔ‰h—{ŠwDˆãŽ•–òo”Å@2015”N3ŒŽ20“ú
  4. ’|“c@ÈAŠÖ@”Ž”Vi•ÒWjDŽ™“ª‰º~“x‚Ì•]‰¿‚ÆççŽq‹•Øp@ˆÀ‘SEŠmŽÀ‚È‹zˆøEççŽq•ª•؂̂½‚ß‚ÉDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N4ŒŽ1“ú
  5. ’|“c@È@ŠÄC “ú–{ŽY‰È–ƒŒŠw‰ïD–³’É•ª•؂̂·‚·‚ßD–ˆ“úV•·o”Å@2015”N4ŒŽ1“ú
  6. –q–ì^‘¾˜YA’|“c@È i‹¤’˜E’S“–•ÒWjA•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾DOGS Now 22@Žèp‚ð—v‚·‚éŽY•wl‰È‹~‹}@‚±‚ñ‚ȂƂ«‚Ç‚¤‚·‚éHíˆÊ‘Ù”Õ‘Šú”—£‚̒鉤؊JpDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N5ŒŽ10“ú
  7. ˆË“¡’ŽuA’|“c@ƒA’|“c@Èi‹¤’˜E’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾DOGS Now 22@Žèp‚ð—v‚·‚éŽY•wl‰È‹~‹}@‚±‚ñ‚ȂƂ«‚Ç‚¤‚·‚éH’oŠÉoŒŒiŒoäT•ª•ØjDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N5ŒŽ10“ú
  8. ‹e’n@”ÕAŒFØ@‡A’|“c@Èi‹¤’˜E’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾DOGS Now 22@Žèp‚ð—v‚·‚éŽY•wl‰È‹~‹}@‚±‚ñ‚ȂƂ«‚Ç‚¤‚·‚éHŽq‹{“à–ŒÇ«—‘‘ƒ”X–EDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N5ŒŽ10“ú
  9. ’|“c@È@(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’å@’†‘l–¯‰ð•úŒR‘æ202ˆã‰@•wŽY‰È•›‹³ŽöDOGS Now 3 (’†‘”Å)@• Ž®’PƒŽq‹{‘S“Ep@Šî–{Žè‹Z‚ÌŠ®‘Sƒ}ƒXƒ^[ ‘O’u‘Ù”ÕA‘O’u–ü’…‘Ù”ÕDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@’†‘”Å2016”N6ŒŽ
  10. “c’†—˜—²A’|“c@È@(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’å@’†‘l–¯‰ð•úŒR‘æ202ˆã‰@•wŽY‰È•›‹³ŽöDOGS Now 3 (’†‘”Å)@• Ž®’PƒŽq‹{‘S“Ep@Šî–{Žè‹Z‚ÌŠ®‘Sƒ}ƒXƒ^[ ’鉤؊JŽž‚Ì‘å—ÊoŒŒ‚̑Έ–@DƒƒWƒJƒ‹ƒrƒ…[ŽÐ@’†‘”Å2016”N6ŒŽ
  11. –q–ì^‘¾˜YA’|“c@È@(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’å@’†‘l–¯‰ð•úŒR‘æ202ˆã‰@•wŽY‰È•›‹³ŽöDOGS Now 3@(’†‘”Å)@• Ž®’PƒŽq‹{‘S“Ep@Šî–{Žè‹Z‚ÌŠ®‘Sƒ}ƒXƒ^[ p’†EpŒãŠÇ—DƒƒWƒJƒ‹ƒrƒ…[ŽÐ@’†‘”Å2016”N6ŒŽ
  12. Ž›”ö‘׋vA–q–ì^‘¾˜YA’|“c@È (•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’åDOGS Now 23@Šo‚¦‚Ä‚¨‚«‚½‚¢Žèp‚ÌH•v‚ÆŽüpŠúŠÇ—@‚³‚Ü‚´‚܂ȋǖʂŖ𗧂Žè‹Z‚Æ’mޝ Žèp’†‚Ì‹}•ϑΉž@‘åoŒŒ‚ւ̑Ήž@ŽY•wl‰Èˆã‚Ì—§ê‚©‚çDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N8ŒŽ10“ú
  13. –q–ì^‘¾˜YA’|“c@È(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’åDOGS Now 23@Šo‚¦‚Ä‚¨‚«‚½‚¢Žèp‚ÌH•v‚ÆŽüpŠúŠÇ—@‚³‚Ü‚´‚܂ȋǖʂŖ𗧂Žè‹Z‚Æ’mޝ Žèp’†‚Ì‹}•ϑΉž@p’†S’âŽ~‚Æ‚»‚̑ΉžDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N8ŒŽ10“ú
  14. ’nŽå@½A’|“c@È(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’åDOGS Now 23@Šo‚¦‚Ä‚¨‚«‚½‚¢Žèp‚ÌH•v‚ÆŽüpŠúŠÇ—@‚³‚Ü‚´‚܂ȋǖʂŖ𗧂Žè‹Z‚Æ’mޝ ŽüpŠúŠÇ—‚Ì•K{’mޝ@Enhanced Recovery After Surgery; ERAS@•wl‰È• o‹¾Žèp‚Ö‚Ì“K‰žDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N8ŒŽ10“ú
  15. Ž•½’•¶A’|“c@È(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’åDOGS Now 23@Šo‚¦‚Ä‚¨‚«‚½‚¢Žèp‚ÌH•v‚ÆŽüpŠúŠÇ—@‚³‚Ü‚´‚܂ȋǖʂŖ𗧂Žè‹Z‚Æ’mޝ “à‰È޾㇕¹—á‚ÌŽüpŠúŠÇ—@SEŒŒŠÇ޾гDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N8ŒŽ10“ú
  16. “¡–ìˆê¬A’|“c@È(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’åDOGS Now 23@Šo‚¦‚Ä‚¨‚«‚½‚¢Žèp‚ÌH•v‚ÆŽüpŠúŠÇ—@‚³‚Ü‚´‚܂ȋǖʂŖ𗧂Žè‹Z‚Æ’mޝ “à‰È޾㇕¹—á‚ÌŽüpŠúŠÇ—@ŒÄ‹zŠí޾гDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N8ŒŽ10“ú
  17. ‹à“c—eGA’|“c@È(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’åDOGS Now 23@Šo‚¦‚Ä‚¨‚«‚½‚¢Žèp‚ÌH•v‚ÆŽüpŠúŠÇ—@‚³‚Ü‚´‚܂ȋǖʂŖ𗧂Žè‹Z‚Æ’mޝ “à‰È޾㇕¹—á‚ÌŽüpŠúŠÇ—@ŠÌ޾гDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N8ŒŽ10“ú
  18. ’|“c@È@(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾DOGS Now 24 “`‚¦‚½‚¢Ž„‚ÌŽèp@Art‚ÆScience‚Ì—Z‡@“®‰æ‚Å“`Žö‚·‚éŽY•wl‰ÈŽèp‚Ì‹†‚Ý ‹‘åŽq‹{èò•”‹ØŽîŠjopDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N11ŒŽ10“ú
  19. •½¼—SŽi@ŸN–͖ؔ¾@¬¼ˆè¶@’|“c@ÈDOGS Now 24 “`‚¦‚½‚¢Ž„‚ÌŽèp@Art‚ÆScience‚Ì—Z‡@“®‰æ‚Å“`Žö‚·‚éŽY•wl‰ÈŽèp‚Ì‹†‚Ý ŽY•wl‰ÈŽèp‚ð‹†‚ß‚é@‰·ŒÌˆçV‚©‚çg‚í‚´h‚ð–‚­ƒRƒcDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N11ŒŽ10“ú
  20. ’|“c@ƒA’|“c@ÈDíˆÊ‘Ù”Õ‘Šú”—£@MFICUƒ}ƒjƒ…ƒAƒ‹ ‘S‘ŽüŽYŠúˆã—ØA—‹¦‹c‰ï@•Ò’˜DƒƒfƒBƒJo”Å@2015”N8ŒŽ1“ú
  21. ’|“c@ÈD‡“V“°Ž®–³’É•ª•ØDƒkƒ“ƒN@2015”N11ŒŽ25“ú
  22. ’|“c@ƒA’|“c@ÈDŽY‰ÈoŒŒ/oŒŒ«ƒVƒ‡ƒbƒN/Á”ï«‹ÃŒÅáŠQ@“Á•Ê•ÒW@‰ªŒ³˜a•¶@EREICU‚ł̖ò‚ÌŽg‚¢•ûEl‚¦•û@ƒGƒLƒXƒp[ƒg‚ÌŽÀ‘H‚Ɣ錂Ɋw‚Ô@2016\f17D‹~‹}EW’†Ž¡—à 27 :e261-267, 2015
  23. –q–ì^‘¾˜Y@’|“c ÈDŽ©•ª‚ÌƒŠƒXƒN‚ð’m‚Á‚ÄŽY‰@‚ð‘I‚Ú‚¤DHUMAN + —‚Æ’j‚̂̃fƒBƒNƒVƒ‡ƒiƒŠ[
  24. –q–ì^‘¾˜YD”DP‚ŒŒˆ³ÇŒóŒQ‚Ìf—ÃŽwj2015DƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N3ŒŽ24“ú
  25. –q–ì^‘¾˜YD—§‰ï‚¢oŽYA‚»‚Ì‘O‚ɂł«‚邱‚Æ‚Á‚ÄHDBaby+
  26. –q–ì^‘¾˜Y@’|“c ÈDŽ©•ª‚ÌƒŠƒXƒN‚ð’m‚Á‚ÄŽY‰@‚ð‘I‚Ú‚¤DHUMAN + —‚Æ’j‚̂̃fƒBƒNƒVƒ‡ƒiƒŠ[ 2015
  27. •½ˆäç—T@’|“cÈD‚¨‚È‚©‚̂͂èE’ɂ݃KƒCƒhƒ‰ƒCƒ“DHUMAN+, —‚Æ’j‚̂̃fƒBƒNƒVƒ‡ƒiƒŠ[2015, P32
  28. •½ˆäç—T@’|“cÈDØ”——¬ŽYEØ”—‘ŽY‚ÆŒ¾‚í‚ꂽ‚çDHUMAN+, —‚Æ’j‚̂̃fƒBƒNƒVƒ‡ƒiƒŠ[2015, P40-41
“Á•Êu‰‰Eµ‘Òu‰‰“™ i‘Ûj
  1. Mari KitadeDReduced Port Surgery (RPS) for Benign TumorDAPAGE workshop (Shanghai, China@2015/3/27-28)
  2. Mari KitadeDIntroduction of tne animal training for laparoscopic surgeryDAPAGE-JSGOE Workshop@(Fukuoka, Japan 2015,8)
  3. Kitade M, Kumakiri J, Kuroda K, Jinushi M, Takeda SDOptimal Management in DIE@Surgical Management and Pathological Findings for DIE and CRE (Colorectal Endometriosis)DAPAGE 16th Annual Congress (Beijing, China 2015/11/5-8).
  4. Oota TDPort site metastasis in laparoscopic surgery. ~etiology and prevention~DAPAGE workshop (Shanghai, China@2015/3/27-28)
  5. Keiji KurodaDElevated serum TSH is associated with decreased AMH in infertile women of reproductive ageDThe 22nd World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI), (Budapest Hungary, 2015/9/17-19)
“Á•Êu‰‰Eµ‘Òu‰‰“™ i‘“àj
  1. ’|“c@ÈD¶ŠUŒ¤CƒvƒƒOƒ‰ƒ€@“ú–{ŽY•wl‰Èˆã‰ï‹¤“¯ƒvƒƒOƒ‰ƒ€/ 4. •ª•ØŠÇ—‚ÌŠî–{‚ðŒ©’¼‚·u“àfŠŒ©‚ł̎™“ª‚Ì‚‚³‚Ì•\Œ»‚ÉŠÖ‚·‚é’ñŒ¾v|ˆÀ‘S‚È‹}‘¬‹•Øp‚Ì‚½‚ß‚É|D‘æ67‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwp‘ (‰¡•l 2015/4/9-12)
  2. ’|“c@ÈA–ko^—D–ÍŒ^‚ðŽg‚Á‚½ççŽqE‹zˆø•ª•Ø,ƒhƒ‰ƒCƒ‰ƒ{‚ð—p‚¢‚½•wl‰È• o‹¾‰ºŽè‹ZuKD‘æ4‰ñŽY•wl‰ÈuÀŒ¤C‰ï@(“Œ‹ž 2015/5/16)
  3. ’|“c@ÈD‘ÙŽ™S”ƒ‚ƒjƒ^ƒŠƒ“ƒO‚̓ǂݕûD‘æ2‰ñ‰z’JŽs—§•a‰@NSTŒ¤‹†‰ï (é‹Ê 2015/5/22)
  4. ’|“c@ÈDŽY‰ÈŠë‹@“IoŒŒ‚ւ̑Ήž@•ª•ØŽæ‚舵‚¢ˆêŽŸŽ{݂ł̑ΉžD“Œ‹ž—Žqˆã‘åŽY•wl‰ÈuÀ“¯–å‰ï‘‰ï@(“Œ‹ž 2015/6/13)
  5. ’|“c@ÈD‹ß–¢—ˆ‚ÌŽüŽYŠúˆã—ÃD‘æ17‰ñ“ú–{•꫊ŌìŠw‰ïŠwpW‰ï@(“Œ‹ž 2015/6/28)
  6. ’|“c@ÈDŽY‰ÈŠë‹@“IoŒŒ‚̑Ήž@‹ÇŠŽ~ŒŒ‚©ŒŒ—¬ŽÕ’f‚©D‘æ34‰ñŽOdŒ§¶ŠU‹³ˆç“Á•ÊŒ¤CƒZƒ~ƒi[@(ŽOd 2015/9/3)
  7. ’|“c@ÈD”DP‚ŒŒˆ³ÇŒóŒQ‚ÌŠÇ—D‘æ7‰ñ‹ž“sŽY•wl‰È‹~‹}f—ÃŒ¤‹†‰ï@(‹ž“s 2015/10/4)
  8. ’|“c@ÈDŽY‰È‹~‹}‚ÆÅ‹ß‚Ì“®ŒüD•½¬27”N“xŒFŒ§•ê‘̕یì–@Žw’èˆãŽtŒ¤C‰ï@(ŒF–{ 2015/11/7)
  9. ’|“c@ÈDŽY‰ÈŠë‹@“IoŒŒ‚̑ΉžDÎ쌧ŽY•wl‰Èˆã‰ïEÎ쌧ŽY‰È•wl‰ÈŠw‰ï“Á•Êu‰‰‰ï@(‹à‘ò 2015/12/13)
  10. ’|“c@ÈDŽ„‚ÌŽY•wl‰ÈŽèpŒ¤C@\\ޏ”s‚ÆH•v\\D–¼ŒÃ‰®‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È@(–¼ŒÃ‰® 2015/12/17)
  11. –ko^—AŒF؇A•“cŒbŽiA’nŽå½A’|“cÈDˆÀ‘S‚È• o‹¾‰ºƒ_ƒOƒ‰ƒXâ|ŠJ•úp‚ׂ̜̈”Õ‰ð–U‚Ì’mޝ‚ƃXƒgƒ‰ƒeƒW[D‘æ36‰ñ“ú–{ƒGƒ“ƒhƒƒgƒŠƒI[ƒVƒXŠw‰ïŠwpu‰‰‰ï @(“Œ‹ž 2015/1/24-25)
  12. –ko^—D• o‹¾Žèp‚Ì‘n‘¢A‰üŠvA ‚»‚µ‚Ä–¢—ˆ @-•“à—T”V‚Ì7‚‚̋³‚¦- (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[jD‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  13. –ko^—DƒgƒbƒvƒAƒXƒŠ[ƒg‚©‚çŠw‚ÔŒŽŒo‚Ì•s’²Ž•ž‚Ì”éŒ|—«‚ÌQOLŒüã‚ÉŒü‚¯‚Ä| eŽq‹{“à–ŒÇf(Žs–¯ŒöŠJuÀjD‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  14. –ko^—D—«ƒAƒXƒŠ[ƒg‚ÌŒŽŒoˆÙí‚Æ”æ˜JœÜ@\‹£‹ZƒpƒtƒH[ƒ}ƒ“ƒXŒüã‚Ì‚½‚߂Ɏ„’B‚ª‚Å‚«‚鎖\Dç—tŽsŽs–¯ŒöŠJuÀ@(ç—t)
  15. –ko^—D‡@• o‹¾‰ºŽq‹{‘ÌŠàŽèp‚Ì —§‚¿ã‚°‚܂ł̌oˆÜ‚ƃgƒŒ[ƒjƒ“ƒOA‡Aƒpƒ‰ƒŒƒ‹–@‚Ås‚¤ • o‹¾‰ºŽq‹{‘ÌŠàŽèp -Žèp‚̃Xƒgƒ‰ƒeƒW[‚Ƈ•¹Ç‘Îô-DŽq‹{‘ÌŠàƒZƒ~ƒi[@(“Œ‹ž)
  16. –ko^—D‡@• o‹¾‰ºŽq‹{‘ÌŠàŽèp‚Ì —§‚¿ã‚°‚܂ł̌oˆÜ‚ƃgƒŒ[ƒjƒ“ƒOA‡Aƒpƒ‰ƒŒƒ‹–@‚Ås‚¤ • o‹¾‰ºŽq‹{‘ÌŠàŽèp -Žèp‚̃Xƒgƒ‰ƒeƒW[‚Ƈ•¹Ç‘Îô-DŽq‹{‘ÌŠàƒZƒ~ƒi[ (‰ªŽRE‘q•~)
  17. –ko^—D’†Œã”N‚É‚¨‚¯‚éŽq‹{“à–ŒÇ «”X–E‚ÌŽæ‚舵‚¢\Šà‰»‚ÌƒŠƒXƒN‚ÆŽèp—Ö@\D‘æ6‰ñ—«ƒzƒ‹ƒ‚ƒ“ˆË‘¶«Ž¾Š³Œ¤‹†‰ï (“Œ‹žj
  18. –ko^—D—«‚̃‰ƒCƒtƒXƒe[ƒW‚ðˆÓޝ‚µ‚½ Žq‹{“à–ŒÇ‚Ìƒ}ƒl[ƒWƒƒ“ƒgD”ŸŠÙ“àŽ‹‹¾Œ¤‹†‰ï i”ŸŠÙj
  19. –ko^—D• o‹¾ŽèpƒXƒLƒ‹ƒAƒbƒv‚̃Rƒc‚Æ‹³ˆç–@ `“àŽ‹‹¾‹Zp”F’èŽæ“¾‚܂łÌS\‚¦‚ÆŽw“±ˆã‚Ì‚ ‚è•û`DŽœŒbˆã‰È‘åŠwW’k‰ï i“Œ‹žj
  20. –ko^—D—«ƒAƒXƒŠ[ƒg‚Ì”–â‘è@\—«ƒAƒXƒŠ[ƒg‚ÌŽOŽå’¥‚ÆŒŽŒoŽž‚Ì•s’²\D‰¡•lˆã‰ï’è—á‰ï i‰¡•lj
  21. –ko^—D[•”Žq‹{“à–ŒÇ‚Æ”X–E«‘B‹ØÇ‚Ìpathogenesis‚©‚ç‚Ý‚½ŠÇ—ŽwjDJapan Endometriosis Forum i“Œ‹žj
  22. –ko^—D—«ƒAƒXƒŠ[ƒg‚̈ãŠw“I‚È”–â‘è@ [‹£‹ZƒpƒtƒH[ƒ}ƒ“ƒXŒüã‚Ì‚½‚߂Ɏ„’B‚ª‚Å‚«‚鎖[DŒc‰ž‘åŠwƒXƒ|[ƒcˆãŠwŒ¤‹†‰ï i‰¡•lj
  23. –ko^—D“]ˆÚ”\‚ðŠl“¾‚µ‚½benign cancer `Žq‹{“à–ŒÇ‚Ìƒ}ƒl[ƒWƒƒ“ƒg‚Æ •a—Šw“IlŽ@`D‘æ113‰ñ‚¨’ƒ‚Ì…‚ª‚ñŠwƒAƒJƒfƒ~ƒA@(“Œ‹ž 2015/4/15)
  24. –ko^—AŒF؇A•“cŒbŽiA’nŽå½A’|“cÈD40Η«‚ÌŽq‹{‹ØŽîE Žq‹{“à–ŒÇ‚ÌŽæ‚舵‚¢[—«‚Ì”N—î‚Æƒ‰ƒCƒtƒXƒ^ƒCƒ‹‚É‘¦‚µ‚½Ž¡—ÃŽwj‚Ì’ñˆÄ[D‘æ30‰ñ“ú–{—«ˆãŠw‰ïŠwpW‰ï (–¼ŒÃ‰® 2015/11/7-8)
  25. –ko^—AŒF؇A•“cŒbŽiA’nŽå½A’|“cÈD•wl‰È—̈æ‚É‚¨‚¯‚é2‘åƒ|[ƒg”z’u‚Ì“Á«‚ÆŽw“EpŽ®‚ÌŒŸ“¢D‘æ28‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (‘åã 2015/12/10-12)
  26. Ž›”ö@‘׋vDICT‚Æl‚ÅŒq‚®‚ª‚ñˆã—ÈÛVƒvƒ‰ƒ“@u•wl‰È‚ª‚ñŽ¡—Âɂ¨‚¯‚é• o‹¾Žèp‚Ì‚ ‚è•û‚Æ“W–]v@D129Žq‹{‘Ì‚ª‚ñ‚ɑ΂·‚é’áNP‰»Ž¡—Ã‚Ö‚ÌŽŽ‚ÝD•½¬27•¶•”‰ÈŠwÈ‚ª‚ñƒvƒƒtƒFƒbƒVƒ‡ƒiƒ‹—{¬Šî”Õ„iƒvƒ‰ƒ“ (ŠâŽè 2015/9/2)
  27. Ž›”ö@‘׋vD‚±‚ê‚©‚çŽn‚ß‚él‚Ì‚½‚߂̕ o‹¾‰ºƒŠƒ“ƒpߊs´p‚ÌH•v‚Æ‘ÎôD‘æ3‰ñ“Œ‹ž’áNP•wl‰ÈŽèpŒ¤‹†‰ï (“Œ‹ž 2015/2/21)
  28. ŒF؇DV¢‘ã‚Ì‹C• ƒ}ƒlƒWƒƒ“ƒgƒVƒXƒeƒ€-•wl‰È• o‹¾‰ºŽèp‚É‚¨‚¯‚é‹C• ŠÂ‹«‚Ìd—v«-D‘æ28‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (‘åã 2015/12/10-12)
  29. ŒF؇D[•”Žq‹{“à–ŒÇ‚É‘Î‚·‚é• o‹¾Žèp@ˆÀ‘S«‚ÆÄŒ»«‚ÌŒüã‚ÉŒü‚¯‚Ä ƒ_ƒOƒ‰ƒXâ|[•”Žq‹{“à–ŒÇ‚É‘Î‚·‚é• o‹¾‰ºŽèp‚̈Ӌ`D‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  30. ŒF؇DElephant in the abdominal cavity`“d“®ƒ‚ƒ‹ƒZƒŒ[ƒ^[‚É‚æ‚éˆÀ‘S‚ÈŒŸ‘̉ñŽû‚ð–ÚŽw‚µ‚Ä`D‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  31. ŒF؇D‹@”\‰·‘¶‚ð–Ú“I‚Æ‚µ‚½Žq‹{“à–ŒÇ‚É‘Î‚·‚é• o‹¾‰ºŽèpD‘æ36‰ñ“ú–{ƒGƒ“ƒhƒƒgƒŠƒI[ƒVƒXŠw‰ïŠwpu‰‰‰ï @(“Œ‹ž 2015/1/24-25)
  32. ‘¾“c„ŽuDƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“@APAGE Fellowship Training Course‚ÉŽQ‰Á‚µ‚ÄD‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  33. Oota TDDoxorubicin hydrochloride and Bevacizumab for the patients with Platinum-taxane resistant Recurrent ovarian cancerD‘æ57‰ñ“ú–{•wl‰ÈŽîᇊw‰ï@(ŠâŽè, 2015/8/7-9)
  34. –q–ì^‘¾˜YDŽY‰È‘å—ÊoŒŒ‚ÌŽ~ŒŒ–@E—AŒŒ–@D‰ªŽR•ŽYŽt‰ï
  35. –q–ì^‘¾˜YDƒvƒƒQƒXƒeƒƒ“‚Æ‘ŽYD‘æ4‰ñƒvƒƒQƒXƒg\ƒQƒ“Œ¤‹†‰ï@(“Œ‹ž 20155/24)
  36. –q–ì^‘¾˜YDŽüŽYŠú—̈æ‚É‚¨‚¯‚éVTE‚ÌŒ»óD‡“V“°DVTŒ¤‹†‰ï
  37. –q–ì^‘¾˜YDŽüŽYŠú—̈æ‚É‚¨‚¯‚éŋ߂̃gƒsƒbƒNƒX (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)D‘æ12‰ñŽüŽYŠúƒƒ“ƒ^ƒ‹ƒwƒ‹ƒXŒ¤‹†‰ï@(“È–Ø 2015/10/31-11/1)
  38. –q–ì^‘¾˜YD’鉤؊J‚̋ؑw–D‡ (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)D‘æ51‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï@(•Ÿ‰ª 2015/7/10-12)
  39. –q–ì^‘¾˜Y@•½ˆäç—T@’|“c@ƒ@ˆÉ“¡—z‰î@ˆîŠ_“OŒP@”‘q“Ö•v@’|“c@ÈD‘O’u–ü’…‘Ù”Õ ‘O’u–ü’…‘Ù”Õ‚Ìp’†f’f‚Æ‚»‚ê‚ɉž‚¶‚½Ž~ŒŒ–@‚Ì‘I‘ðiƒVƒ“ƒ|ƒWƒEƒ€jD‘æ51‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï@(•Ÿ‰ª 2015/7/10-12)
  40. –q–ì ^‘¾˜Y, •½ˆä ç—T, ’|“c ƒ, ²–ì–õŽq,“‡ŠÑ —m‘¾, ”‘q “Ö•v, ’|“c ÈD‘ÙŽ™S””ƒ‚ƒjƒ^ƒŠƒ“ƒO‚ÆŽžŠÔ޲iƒVƒ“ƒ|ƒWƒEƒ€jD‘æ38‰ñ•ê‘َ̑™ˆãŠw‰ïŠwpW‰ï@(•Ê•{ 2015/10/29-30)
  41. –q–ì ^‘¾˜Y, •½ˆä ç—T, ’|“c ƒ, “‡ŠÑ —m‘¾, ˆË“¡ ’Žu, ”‘q “Ö•v, ’|“c ÈDŽq‹{“àƒ^ƒ“ƒ|ƒi[ƒf–@‚Ì—v’ú@“K—p‚ÆŒÀŠE Žq‹{“àƒoƒ‹[ƒ“ƒ^ƒ“ƒ|ƒi[ƒf‚É‚æ‚éŽ~ŒŒ‚ÌŒÀŠE‚Æ‚»‚Ì‘Îô@iƒVƒ“ƒ|ƒWƒEƒ€jD‘æ130“ú–{ŽY‰È•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ïiç—t@2015/10/25-26j
  42. –q–ì^‘¾˜Y@ •ì@K ’|“c@ƒ •½ˆäç—T@“‡ŠÑ—m‘¾@ Šp‘qOs@”‘q“Ö•v ’|“c@ÈD‹}‘¬‹•ØiƒVƒ“ƒ|ƒWƒEƒ€jD‘æ119‰ñ“ú–{ŽY‰È–ƒŒŠw‰ïŠwpW‰ï@(“Œ‹ž 2015/11/28-29)
  43. –q–ì ^‘¾˜Y, •½ˆä ç—T, ”‘q “Ö•v, ’|“c È, Šp‘q OsDƒTƒuƒXƒyƒVƒƒƒŠƒeƒB[‚Æ‚µ‚Ă̎Y‰È–ƒŒ‚̈Ӌ`‚Æ‚Í ‡“V“°‘åŠw‚É‚¨‚¯‚éŽY‰È–ƒŒƒ`[ƒ€Ý—§‘OŒã‚ÌŽüŽYŠúˆã—Â̕ω»iƒVƒ“ƒ|ƒWƒEƒ€jD‘æ35‰ñ—Õ°–ƒŒŠw‰ïŠwpW‰ï@(‰¡•l 2015/10/21-23)
  44. Keiji KurodaDElevated serum TSH is associated with decreased AMH in infertile women of reproductive ageDThe 22nd World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI), Budapest Hungary, 2015”N9ŒŽ17“ú\19“ú
  45. •“cŒbŽiDŽq‹{“à–Œ’E—Ž–Œ‰»‰ß’ö‚É‚¨‚¯‚é ƒRƒ‹ƒ`ƒRƒXƒeƒƒCƒhEƒŒƒ`ƒmƒCƒhƒVƒOƒiƒ‹Œo˜HD‘æ113‰ñ‚¨’ƒ‚Ì…‚ª‚ñŠwƒAƒJƒfƒ~ƒA@(“Œ‹ž 2015/4/15)
  46. •“cŒbŽiD“V‘RŒ^ƒvƒƒQƒXƒeƒƒ“»Ü‚ÉŠú‘Ò‚·‚é ’…°‚â—¬ŽY‚Ö‚ÌŒø‰ÊDÅ“K‚È•s”DŽ¡—ÃJƒ“ƒtƒ@ƒŒƒ“ƒX (“Œ‹ž 2015/6/5)
  47. •“cŒbŽiD¶Bˆã—Âɂ¨‚¯‚é “V‘RŒ^ƒvƒƒQƒXƒeƒƒ“»Ü‚ÌV‚½‚ȉ”\« [Žq‹{“à–Œ‚ÌŒ¤‹†ƒf[ƒ^‚ðŠî‚É[D‘æ33‰ñ“ú–{Žó¸’…°Šw‰ï‘‰ïEŠwpu‰‰‰ï (2015/11/26-27)
  48. •“cŒbŽiDESHRE Highlights: Implantation Potential & Fertility PreservationD‘æ33‰ñ“ú–{Žó¸’…°Šw‰ï‘‰ïEŠwpu‰‰‰ï (2015/11/26-27)
  49. •“cŒbŽiDƒ‰ƒCƒtƒXƒe[ƒW‚ɉž‚¶‚½ Žq‹{“à–ŒÇ‚Ìƒ}ƒl[ƒWƒƒ“ƒgD‰F“s‹{ŽY•wl‰Èˆã‰ï@“ñ‹à‰ï (“È–Ø 2015/11/13)
  50. ’nŽå@½DŽq‹{“à–ŒÇ‚É‘Î‚·‚é• o‹¾‰ºŽèp@iƒXƒ|ƒ“ƒT[ƒhƒVƒ“ƒ|ƒWƒEƒ€jD‘æ36‰ñ“ú–{ƒGƒ“ƒhƒƒgƒŠƒI[ƒVƒXŠw‰ïŠwpu‰‰‰ï @(“Œ‹ž 2015/1/24-25)
  51. ’nŽå@½DˆÀ‘S‚És‚¦‚éTLHE• o‹¾‰ºˆ««Žîᇎèp `ÅV‹@Ší‚ÌŽg—p•û–@‚ƃ|ƒCƒ“ƒg` (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[jD‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  52. ’nŽå@½DŽq‹{“à–ŒÇ‚É‘Î‚·‚é• o‹¾‰ºŽèp@iƒVƒ“ƒ|ƒWƒEƒ€jD‘æ28‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (‘åã 2015/12/10-12)
  53. ’nŽå@½DERASƒvƒƒgƒR[ƒ‹‚ð‚à‚Æ‚É• o‹¾‰ºŽèpгŽÒ‚ɑ΂µ‚Ä“±“ü‚µ‚½p‘OŒoŒû•â…‚Ì•û–@‚Æ‚»‚ÌŒø‰ÊD‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  54. ”öú±—Œb, ŒFØ@‡,–ko^—, ’|“c@ÈDpŒãpoor ovarian responder ‰ñ”ð‚Ì‚½‚ß‚Ì —‘‘ƒƒ`ƒ‡ƒRƒŒ[ƒg”X–E‚ɑ΂·‚é • o‹¾‰º”X–E“Eop‚Ì“K‰ž‚ÌÄlD‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  55. ’|“cƒA–q–ì^‘¾˜YA”‘q“Ö•vA’|“cÈD“–‰@‚É‚¨‚¯‚é• o‹¾‰ºŽq‹{‹ØŽîŠjopŒã”DP‚ÌŠÇ—D‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  56. ’|“cƒD–³’É•ª•؂ɂ¨‚¯‚镪•Ø‘£iD‘æ119‰ñ“ú–{ŽY‰È–ƒŒŠw‰ïŠwpW‰ï@(“Œ‹ž 2015/11/28-29)
‚»‚Ì‘¼iL•ñŠˆ“®‚ðŠÜ‚Þj
  1. ’|“c@ÈDŽq‹{‹ØŽîD¹‹³V•·7•Å2ŒŽ8“ú
  2. ’|“c@È •ÒW@ã–ì‰ë´D”­Š§‚ÉŠñ‚¹‚Ä@‡“V“°Žj‚©‚ç‚Ý‚½ŽY•wl‰È—ïD‡“V“°‘åŠwˆãŠw•”ŽY•wl‰ÈŠwuÀ“¯‘‹‰ï@•½¬27”N4ŒŽ1“ú
  3. ’|“c@È •ÒW@ã–ì‰ë´D–{–@‰‚̒鉤؊Jp‚Ƈ“V“°@‡“V“°Žj‚©‚ç‚Ý‚½ŽY•wl‰È—ïD‡“V“°‘åŠwˆãŠw•”ŽY•wl‰ÈŠwuÀ“¯‘‹‰ï@•½¬27”N4ŒŽ1“ú
  4. ’|“c@ÈAŠÖ@”Ž”Vi•ÒWjDŽ™“ª‰º~“x‚Ì•]‰¿‚ÆççŽq‹•Øp ˆÀ‘SEŠmŽÀ‚È‹zˆøEççŽq•ª•؂̂½‚ß‚É ˜•¶DƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N4ŒŽ1“ú
  5. ‘è ‰p–¾ , ’|“c È , ’r“c ’q–¾ , –Ø‘º ³ , H“¡ ”üŽ÷ , ‹v•Û —²•F , âV“¡ Ž  , ²“¡ ¹Ži , ™‰Y ^‹| , ` —˜”V , “¡X Œh–ç , …ã ®“TDŽüŽYŠúˆÏˆõ‰ï(•½¬27”N“xê–åˆÏˆõ‰ï•ñ)D“ú–{ŽY‰È•wl‰È›{˜ðè¶Ž 67(6), 1517-1566, 2015-06-01
  6. Œ¤‹†‘ã•\ŽÒ@“¡Œ´@Œbˆê@Œ¤‹†‹¦—ÍŽÒ@’|“c@ÈD•½¬27”N“xŒú¶˜J“­‰ÈŠwŒ¤‹†”ï•â•‹àˆã—ËZpŽÀ—p‰»‘‡Œ¤‹†Ž–‹Æ
  7. is—‘‘ƒŠàE—‘ŠÇŠàE• –ŒŠà‚ɑ΂·‚é• o“à‰»Šw—Ö@Šm—§‚Ì‚½‚߂̌¤‹†@•½¬26”N“x@‘ЇŒ¤‹†•ñ‘D•½¬27”N3ŒŽ
  8. ƒZƒ“ƒ^[’·@¬Š}Œ´‰xŽq@Œ¤‹†ƒvƒƒWƒFƒNƒgƒƒ“ƒo[@ŒE@–ƒ—R”üA“c“ˆ@“ÖA–ko^—A’|“c@ÈA’r“c˜a”ŽAˆäã@‘A‘¼D•½¬26”N“x‡“V“°‘åŠw‘åŠw‰@ƒXƒ|[ƒcŒ’N‰ÈŠwŒ¤‹†‰È—«ƒXƒ|[ƒcŒ¤‹†ƒZƒ“ƒ^[‹I—v
  9. –ko^—D—«ƒAƒXƒŠ[ƒgŠO—ˆ@ŠJ‚©‚ꂽƒ`[ƒ€ˆã—Âð–ÚŽw‚µ‚ÄD—«ƒXƒ|[ƒcƒIƒ“ƒ‰ƒCƒ“Women in Sport@2015
  10. –ko^—D—«ƒAƒXƒŠ[ƒgŠO—ˆ‚̈Ӌ`‚ƃƒfƒBƒJƒ‹ƒTƒ|[ƒg
  11. \‹£‹ZƒpƒtƒH[ƒ}ƒ“ƒXŒüã‚Ì‚½‚߂Ɏ„’B‚ª‚Å‚«‚鎖\Dˆã—ØAŒg‚ð‹¤‚Él‚¦‚é‰ï. (“Œ‹ž)
  12. –ko^—A‘å{‰êõDŽèp”‚ł킩‚é‚¢‚¢•a‰@ ‘S‘’n•û•ʃ‰ƒ“ƒLƒ“ƒO 2016@-—«‚Ì—Ç«Ž¾Š³-D’©“úV•·o”Å 2015/9/28
  13. –ko^—D2016”N“x”Å@‘–¯‚Ì‚½‚߂̖¼ˆãƒ‰ƒ“ƒLƒ“ƒOD÷‚̉Ôo”Å 2015/11/11
  14. –ko^—Dƒpƒ‰ƒŒƒ‹–@‚Ås‚¤• o‹¾‰ºŽèp‚ł̑Ìo“à–D‡EŒ‹ãFD“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ïŽåÃ@–D‡uK‰ï, 2015 “Œ‹ž
  15. ‘¾“c„ŽuD—‘‘ƒŠà‚Ɖ»Šw—Ö@@--2nd-line‰»Šw—Ö@‚ÌŽ¡—ÑI‘ð--Dƒ„ƒ“ƒZƒ“ƒtƒ@[ƒ}u‰‰‰ï@(“Œ‹ž 2015/8/18)
  16. ‘¾“c„ŽuD—‘‘ƒ‚ª‚ñ‚Ɖ»Šw—Ö@@-2nd-line‰»Šw—Ö@‚Ì‘I‘ð‚ÆƒxƒoƒVƒcƒ}ƒu‚Ì“±“ü-D’†ŠO»–òu‰‰‰ï@(“Œ‹ž 2015/11/12)
  17. –Ø‘º”üˆ¨DŽq‹{èò‚ª‚ñ@`ŒŸf‚©‚玡—Ã`D•iì—ŽqŠw‰@‚Z@(“Œ‹ž 2015/2/14)
  18. –q–ì^‘¾˜YD—§‰ï‚¢oŽYA‚»‚Ì‘O‚ɂł«‚邱‚Æ‚Á‚ÄHD‚¨ˆãŽÒ‚³‚ñ‚ª‚‚­‚Á‚½”DPEoŽY‚Ìî•ñƒTƒCƒg Baby+ https://akasugu.fcart.jp/babyplus/articles/7fgj6/
  19. –q–ì^‘¾˜Y@’|“c ÈDŽ©•ª‚ÌƒŠƒXƒN‚ð’m‚Á‚ÄŽY‰@‚ð‘I‚Ú‚¤DHUMAN + —‚Æ’j‚̂̃fƒBƒNƒVƒ‡ƒiƒŠ[@http://humanplus.jp
  20. –q–ì^‘¾˜YD‚Ó‚½‚²ƒNƒ‰ƒuDBenesse ‚½‚Ü‚²ƒNƒ‰ƒu@(˜AÚ)
  21. •“cŒbŽiDƒf[ƒ^‚©‚çl‚¦‚é‚ ‚È‚½‚Ì”DP—ÍDƒxƒr‘Ò‚¿ƒJƒbƒvƒ‹‚Ì‚½‚߂̎q•óƒZƒ~ƒi[ (“Œ‹ž 2015/7/12)
  22. •“cŒbŽiDŽq‹{“à–ŒÇ‚Ìf’f‚ÆŽ¡—ÃD“ú–{V–òŽÐ“àŒ¤C‰ï (“Œ‹ž 2015/2/24)
  23. Ž•½@’•¶A“¡–ì@ˆê¬A–Ø‘º@”üˆ¨A@‘¾“c@„ŽuAŽ›”ö@‘׋vA’|“c@ÈD“–‰@‚É‚¨‚¯‚éÄ”­Eis—‘‘ƒŠà‚ɑ΂·‚é ƒxƒoƒVƒYƒ}ƒuŽg—pŒoŒ±DTokyo ovarian cancer summit@(“Œ‹ž 2015/6/19)
  24. ²–ì–õŽqA’r–{—TŽqAˆäŽR”üˆ¨A’|“c@ÈD–½‚ðŽx‚¦‚é♥–¢—ˆƒrƒWƒ‡ƒ“À’k‰ï@‚Ç‚¤‚µ‚Ä‚¢‚Ü‚·‚©HŽY•wl‰Èˆã‚ÌuŽdŽ–v‚ÆuŽqˆç‚ÄvDƒAƒlƒeƒBƒX2015‰Ä†
  25. ’|“c@ƒA’|“c@ÈD”D•wŒ’f‚͎󂯂Ȃ¢‚Æ‚¢‚¯‚È‚¢‚ÌH HUMAN+ Baby{@‚¨ˆãŽÒ‚³‚ñ‚ª‚‚­‚Á‚½”DPEoŽY‚Ì–{D“ú–{ŽY‰È•wl‰ÈŠw‰ï@ŠÄC@2015”N9ŒŽ30“ú

Copyright © 2005 JUNTENDO All Rights Reserved.